| Symbol | TSHA |
|---|---|
| Name | TAYSHA GENE THERAPIES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 3000 PEGASUS PARK DRIVE,SUITE 1430, DALLAS, Texas, 75247, United States |
| Telephone | +1 214 612-0000 |
| Fax | — |
| — | |
| Website | https://www.tayshagtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001806310 |
| Description | Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Taysha Gene Therapies, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001231919-26-000928 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G/A - Taysha Gene Therapies, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0000895421-26-000269 <b>Size:</b> 12 KB
Read more(30% Negative) TAYSHA GENE THERAPIES, INC. (TSHA) Reports Q3 2026 Financial Results
Read moreTaysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read moreTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read moreTaysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
Read moreTaysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Read more(99% Neutral) TAYSHA GENE THERAPIES, INC. (TSHA) Announces Clinical Development Update
Read moreTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Read moreNew Form 424B5 - Taysha Gene Therapies, Inc. <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0001193125-26-282846 <b>Size:</b> 2 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07480564 | Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females A… | Phase3 | Rett Syndrome | Recruiting | 2026-05-08 | 2031-06-01 | ClinicalTrials.gov |
| NCT06152237 | Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL… | Phase1 | Rett Syndrome | Active_Not_Recruiting | 2023-12-12 | 2031-11-02 | ClinicalTrials.gov |
| NCT05606614 | A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REV… | Phase3 | Rett Syndrome | Active_Not_Recruiting | 2023-03-06 | 2031-06-01 | ClinicalTrials.gov |
| NCT05277363 | A Study of the Natural Course of SURF1 Deficiency | — | Leigh Syndrome | Withdrawn | 2022-05-04 | 2022-05-04 | ClinicalTrials.gov |
| NCT04798235 | First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset … | Phase1 | Infantile GM2 Gangliosidosis (Disorder) | Active_Not_Recruiting | 2021-03-12 | 2027-03-12 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| TSHA-102 | Other | Phase PHASE3 | Rett Syndrome | ACTIVE_NOT_RECRUITING | NCT05606614 |
| TSHA-102 | Other | Phase PHASE3 | Rett Syndrome | RECRUITING | NCT07480564 |
| TSHA-102 | Other | Phase PHASE3 | Rett Syndrome | RECRUITING | NCT07480564 |
| TSHA-102 | Other | Phase PHASE3 | Rett Syndrome | RECRUITING | NCT07480564 |
| TSHA-102 | Other | Phase PHASE3 | Rett Syndrome | RECRUITING | NCT07480564 |
| TSHA-102 | Other | Phase PHASE3 | Rett Syndrome | RECRUITING | NCT07480564 |
| None (Observational study) | Other | Preclinical | Leigh Syndrome | WITHDRAWN | NCT05277363 |
| TSHA-101 | Other | Phase PHASE1 | Infantile GM2 Gangliosidosis (Disorder) | ACTIVE_NOT_RECRUITING | NCT04798235 |
| TSHA-102 | Other | Phase PHASE1 | Rett Syndrome | ACTIVE_NOT_RECRUITING | NCT06152237 |
| TSHA-102 | Other | Phase PHASE3 | Rett Syndrome | RECRUITING | NCT05606614 |
| TSHA-102 | Other | Phase PHASE3 | Rett Syndrome | NOT_YET_RECRUITING | NCT07480564 |
| TSHA-102 | GENETIC | Phase PHASE3 | Rett Syndrome | NOT_YET_RECRUITING | NCT07480564 |
| None (Observational study) | OTHER | Preclinical | Leigh Syndrome | WITHDRAWN | NCT05277363 |
| TSHA-101 | BIOLOGICAL | Phase PHASE1 | Infantile GM2 Gangliosidosis (Disorder) | ACTIVE_NOT_RECRUITING | NCT04798235 |